Sarah Bray

EU-Wi<i>d</i>e Cross-Section<i>a</i>l Obser<i>v</i>at<i>i</i>o<i>n</i>al Study of Lipid-Modifying Therapy Use in Se<i>c</i>ondary and Pr<i>i</i>mary Care: the DA VINCI study

Kausik K. Ray, Bart Molemans, W. Marieke Schoonen et al. · European Journal of Preventive Cardiology · 2020 · 767 citations · Full text

Medicine, Cardiology, Pharmacotherapy +16

Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study

Michael R. McClung, Jacques P. Brown, Adolfo Díez‐Pérez et al. · Journal of Bone and Mineral Research · 2018 · 231 citations · Full text

Medicine, Pharmacotherapy, Bone Metabolism +16

A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer

Hedy L. Kindler, Donald Richards, Lawrence Garbo et al. · Annals of Oncology · 2012 · 191 citations · Full text

Medicine, Oncology, Pharmacology +14

Long-Term Evolocumab in Patients With Familial Hypercholesterolemia

Raúl D. Santos, Evan A. Stein, G. Kees Hovingh et al. · Journal of the American College of Cardiology · 2020 · 186 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

A functional genomics approach reveals novel quantitative trait loci associated with platelet signaling pathways

Chris I. Jones, Sarah Bray, Stephen F. Garner et al. · Blood · 2009 · 141 citations · Full text

Life Sciences, Genetics, Molecular Genetics +14